HTA agencies facing model biases: the case of type 2 diabetes.

about

Exploring Uncertainty in Economic Evaluations of Drugs and Medical Devices: Lessons from the First Review of Manufacturers' Submissions to the French National Authority for Health.Towards a New Framework for Addressing Structural Uncertainty in Health Technology Assessment Guidelines.

P2860

Q38717853-EC9A133B-E697-46AB-9813-0491A8488F98 Q49629143-1D272D86-E95B-4D4A-8C5C-07FAC626739E

P2860

HTA agencies facing model biases: the case of type 2 diabetes.

Item

http://www.wikidata.org/entity/Q38215010

description

article científic

@ca

article scientifique

@fr

articol științific

@ro

articolo scientifico

@it

artigo científico

@gl

artigo científico

@pt

artigo científico

@pt-br

artikel ilmiah

@id

artikull shkencor

@sq

artículo científico

@es

name

HTA agencies facing model biases: the case of type 2 diabetes.

@en

type

Item

label

HTA agencies facing model biases: the case of type 2 diabetes.

@en

prefLabel

HTA agencies facing model biases: the case of type 2 diabetes.

@en

P1476

HTA agencies facing model biases: the case of type 2 diabetes

@en

P2093

Jean-Michel Josselin

http://www.w3.org/2001/XMLSchema#string

Lise Rochaix

http://www.w3.org/2001/XMLSchema#string

P2860

Effect of intensive glucose lowering treatment on all cause mortality, cardiovascular death, and microvascular events in type 2 diabetes: meta-analysis of randomised controlled trials

Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). UK Prospective Diabetes Study (UKPDS) Group

Effects of intensive glucose lowering in type 2 diabetes

Glucose control and vascular complications in veterans with type 2 diabetes

Cost-effectiveness of insulin analogues for diabetes mellitus.

Newer agents for blood glucose control in type 2 diabetes: systematic review and economic evaluation.

The role of models within economic analysis: focus on type 2 diabetes mellitus.

Cost-effectiveness of second-line antihyperglycemic therapy in patients with type 2 diabetes mellitus inadequately controlled on metformin

Dipeptydil peptidase-4 inhibitors in type 2 diabetes: a meta-analysis of randomized clinical trials.

A meta-analysis of placebo-controlled clinical trials assessing the efficacy and safety of incretin-based medications in patients with type 2 diabetes.

P2888

s40273-014-0172-8

P304

825-839

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1007/S40273-014-0172-8

http://www.w3.org/2001/XMLSchema#string

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P50

Véronique Raimond

P577

2014-09-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

24862533

http://www.w3.org/2001/XMLSchema#string

P921

type-2 diabetes

bias

HTA agencies facing model biases: the case of type 2 diabetes.

about

P2860

P2860

HTA agencies facing model biases: the case of type 2 diabetes.

description

name

type

label

prefLabel

P1433

P1476

P2093

P2860

P2888

P304

P31

P356

P433

P478

P50

P577

P698

P921

P356

P1433

P1476

P2093

P2860

P2888

P304

P31

P356

P433

P478

P50

P577

P698

P921